These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 17014579

  • 1. Effects of phlebotomy therapy on cytochrome P450 2e1 activity and oxidative stress markers in dysmetabolic iron overload syndrome: a randomized trial.
    Lainé F, Reymann JM, Morel F, Langouët S, Perrin M, Guillygomarc'h A, Brissot P, Turmel V, Mouchel C, Pape D, Bellissant E, Deugnier Y.
    Aliment Pharmacol Ther; 2006 Oct 15; 24(8):1207-13. PubMed ID: 17014579
    [Abstract] [Full Text] [Related]

  • 2. Increased urinary excretion of 8-iso-prostaglandin F2alpha in patients with HFE-related hemochromatosis: a case-control study.
    Kom GD, Schwedhelm E, Nielsen P, Böger RH.
    Free Radic Biol Med; 2006 Apr 01; 40(7):1194-200. PubMed ID: 16545687
    [Abstract] [Full Text] [Related]

  • 3. Effects of vitamin E administration on the hemorheological status and redox homeostasis of patients with porphyria cutanea tarda treated with phlebotomy.
    Székely E, Vereckei A, Almási A, Rapavi E, Tasnádi G, Várnai K, Pallai Z, Lugasi A, Blázovics A.
    Clin Hemorheol Microcirc; 2007 Apr 01; 36(1):13-23. PubMed ID: 17211058
    [Abstract] [Full Text] [Related]

  • 4. Chlormethiazole inhibition of cytochrome P450 2E1 as assessed by chlorzoxazone hydroxylation in humans.
    Gebhardt AC, Lucas D, Ménez JF, Seitz HK.
    Hepatology; 1997 Oct 01; 26(4):957-61. PubMed ID: 9328319
    [Abstract] [Full Text] [Related]

  • 5. Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial.
    Zacharski LR, Chow BK, Howes PS, Shamayeva G, Baron JA, Dalman RL, Malenka DJ, Ozaki CK, Lavori PW.
    J Natl Cancer Inst; 2008 Jul 16; 100(14):996-1002. PubMed ID: 18612130
    [Abstract] [Full Text] [Related]

  • 6. A significant reduction in serum alanine aminotransferase levels after 3-month iron reduction therapy for chronic hepatitis C: a multicenter, prospective, randomized, controlled trial in Japan.
    Yano M, Hayashi H, Yoshioka K, Kohgo Y, Saito H, Niitsu Y, Kato J, Iino S, Yotsuyanagi H, Kobayashi Y, Kawamura K, Kakumu S, Kaito M, Ikoma J, Wakusawa S, Okanoue T, Sumida Y, Kimura F, Kajiwara E, Sata M, Ogata K.
    J Gastroenterol; 2004 Jun 16; 39(6):570-4. PubMed ID: 15235875
    [Abstract] [Full Text] [Related]

  • 7. Patient compliance with phlebotomy therapy for iron overload associated with hemochromatosis.
    Hicken BL, Tucker DC, Barton JC.
    Am J Gastroenterol; 2003 Sep 16; 98(9):2072-7. PubMed ID: 14499790
    [Abstract] [Full Text] [Related]

  • 8. Effects of venesections and restricted diet in patients with the insulin-resistance hepatic iron overload syndrome.
    Piperno A, Vergani A, Salvioni A, Trombini P, Viganò M, Riva A, Zoppo A, Boari G, Mancia G.
    Liver Int; 2004 Oct 16; 24(5):471-6. PubMed ID: 15482345
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of phlebotomy to reduce transfusional iron overload in adult, long-term survivors of acute leukemia.
    Franchini M, Gandini G, Veneri D, de Matteis G, Federici F, Solero P, Aprili G.
    Transfusion; 2004 Jun 16; 44(6):833-7. PubMed ID: 15157247
    [Abstract] [Full Text] [Related]

  • 10. Hepatic cytochrome P450 2E1 activity in nonalcoholic fatty liver disease.
    Prompila N, Wittayalertpanya S, Komolmit P.
    J Med Assoc Thai; 2008 May 16; 91(5):733-8. PubMed ID: 18672640
    [Abstract] [Full Text] [Related]

  • 11. Additional effect of low iron diet on iron reduction therapy by phlebotomy for chronic hepatitis C.
    Kimura F, Hayashi H, Yano M, Yoshioka K, Matsumura T, Fukuda T, Shigeto N, Yamahara S, Koushi F, Mishima Y, Yoshino T, Tanimoto M, Kimura I.
    Hepatogastroenterology; 2005 May 16; 52(62):563-6. PubMed ID: 15816478
    [Abstract] [Full Text] [Related]

  • 12. Impaired 6-hydroxychlorzoxazone elimination in patients with kidney disease: Implication for cytochrome P450 2E1 pharmacogenetic studies.
    Nolin TD, Gastonguay MR, Bies RR, Matzke GR, Frye RF.
    Clin Pharmacol Ther; 2003 Dec 16; 74(6):555-68. PubMed ID: 14663458
    [Abstract] [Full Text] [Related]

  • 13. Hepatic oxidative DNA damage correlates with iron overload in chronic hepatitis C patients.
    Fujita N, Horiike S, Sugimoto R, Tanaka H, Iwasa M, Kobayashi Y, Hasegawa K, Ma N, Kawanishi S, Adachi Y, Kaito M.
    Free Radic Biol Med; 2007 Feb 01; 42(3):353-62. PubMed ID: 17210448
    [Abstract] [Full Text] [Related]

  • 14. Early iron reduction programme for thalassaemia patients after bone marrow transplantation.
    Li CK, Lai DH, Shing MM, Chik KW, Lee V, Yuen PM.
    Bone Marrow Transplant; 2000 Mar 01; 25(6):653-6. PubMed ID: 10734300
    [Abstract] [Full Text] [Related]

  • 15. Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study.
    Valenti L, Fracanzani AL, Dongiovanni P, Bugianesi E, Marchesini G, Manzini P, Vanni E, Fargion S.
    Am J Gastroenterol; 2007 Jun 01; 102(6):1251-8. PubMed ID: 17391316
    [Abstract] [Full Text] [Related]

  • 16. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA, Cachofeiro V, Masana L, Suarez C, Pinilla B, Plana N, Trias F, Moreno MA, Gambus G, Lahera V, Pintó X.
    Clin Ther; 2008 Jan 01; 30(1):84-97. PubMed ID: 18343245
    [Abstract] [Full Text] [Related]

  • 17. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J, Ikeda Y, Kuribayashi T, Kajiwara K, Biro S, Yamamoto K, Ageta M, Kobori S, Saikawa T, Otonari T, Kono S.
    Clin Ther; 2008 Jun 01; 30(6):1089-101. PubMed ID: 18640465
    [Abstract] [Full Text] [Related]

  • 18. Long-term course after initial iron removal of iron excess in patients with dysmetabolic iron overload syndrome.
    Bardou-Jacquet E, Lainé F, Morcet J, Perrin M, Guyader D, Deugnier Y.
    Eur J Gastroenterol Hepatol; 2014 Apr 01; 26(4):418-21. PubMed ID: 24557330
    [Abstract] [Full Text] [Related]

  • 19. Metabolic and hepatic effects of bloodletting in dysmetabolic iron overload syndrome: A randomized controlled study in 274 patients.
    Lainé F, Ruivard M, Loustaud-Ratti V, Bonnet F, Calès P, Bardou-Jacquet E, Sacher-Huvelin S, Causse X, Beusnel C, Renault A, Bellissant E, Deugnier Y, Study Group.
    Hepatology; 2017 Feb 01; 65(2):465-474. PubMed ID: 27685251
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.